Fiona Simpkins, M.D.
Hilarie L. and Mitchell L. Morgan President's Distinguished Professor in Women's Health
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Pennsylvania Hospital, Philadelphia, PA
Active Staff, Gynecologic Oncology, Department of Ob/Gyn, Chester County Hospital, West Chester, PA
Director of Clinical & Translational Gynecologic Oncology Research, Penn Medicine Health System
Department: Obstetrics and Gynecology
Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Fax: 215-349-5849
Education
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
Permanent linkB.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
Selected Publications
Yap, TA, Simpkins F, Porte M, Postel-Vinay: Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology. Am Soc Clin Oncol Educ Book Jun 2026.Kim D, Chung H, Abed M, Ma J, Molden N, Shim C, Rajendran D, Yen J, Jeong J, Levy A, Yaniz-Galende E, Blanc-Durand F, Desauw C, Follana P, Bonichon-Lamichhane N, Oudard S, D'Hondt V, Gavoille C, Jandial DD, Meric-Bernstam F, Liu JF, Simpkins F, Randall LM, Leary A, Lackner MR, Harismendy O.: Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer. NPJ Precis Oncol nature, 30(10): 244, May 2026.
Anna Jo Smith , Caroline Shermoen , Stefanie N Hinkle , Nathanael C Koelper , Lisa Mills , Meredith Doherty , Justin E Bekelman , Fiona Simpkins , Emily M Ko : Results of integrating an automated electronic social determinants of health screening survey in a gynecologic oncology practice: a pilot study. Int J Gynecol Cancer 36(5), May 2026.
Jang M, Gysler S, Latif NA, Ko EM, Giuntoli RL 2nd, Kim SH, Simpkins F, Nasioudis D: Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies. Gynecol Oncol Rep Page: 63:102008. doi: 10.1016/j.gore.2025.102008. eCollection, Dec 2025.
Jang M, Gysler S, Latif NA, Ko EM, Giuntoli RL 2nd, Kim SH, Simpkins F, Nasioudis D: Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies. Gynecol Oncol Rep . 2025 Dec 16:63:102008 16(63), Dec 2025.
Onecha VV, Suarez-García D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A: Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace. Int J Radiat Oncol Biol Phys Page: 123(3):656-668. doi: 10.1016/j.ijrobp.2025.05.085, Nov 2025.
Onecha VV, Suarez-García D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A.: Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace. Int J Radiat Oncol Biol Phys. (IF = 6.5) Jun 2025.
Smith AJB, Spataro S, Heintz J, Simpkins F, Ko EM: Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis. Am J Obstet Gynecol. (Impact factor 8) Apr 2025.
Fiona Simpkins, Alexandra Leary, Lyndsay Willmott, Bradley J. Monk, Jean-Sébastien Frenel, David C. Starks, Meena Okera, Angeles Alvarez Secord, David M. O’Malley, Lainie Martin, Kaissa Ouali, Martin K. Oehler, Jeffrey C. Goh, Brian M. Slomovitz, Peter C. Lim, Catherine M. Shannon, Robert Neff, Doris Kim, Hailun Li, Danielle Jandial, Floor J. Backes : Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066) Gynecology Oncology; plenary, SGO Annual Meeting, March 2025 April 2025.
Erin George, Lakeisha Mulugeta-Gordon, Emily M Ko, Sharon Wu, Joanne Xiu, Nathaniel Jones, Premal H Thaker, Thomas J Herzog, Eric J Brown, Dineo Khabele, Fiona Simpkins: Impact of CCNE1 Amplification on Molecular Signatures and Patient Outcomes in High Grade Serous Ovarian and Endometrial Cancer. Gynecology Oncology; plenary, SGO Annual Meeting, March 2025 April 2025.